Efficacy of nivolumab (Nivo) as 2+line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim results of observational prospective study.

被引：1
|
作者：
Laktionov, Konstantin K.
Arzumanyan, Alla L.
Bolotina, Larisa
Breder, Valeriy Vladimirovich
Buevich, Natalia N.
Danilova, Anastasia
Filippova, Elena A.
Kornietskaya, Anna
Kramchaninov, Mikhail M.
Kushniruk, Eugenia K.
Latipova, Dilorom H.
Moiseenko, Fedor Vladimirovich
Nikitina, Tatiana P.
Orlov, Sergey V.
Orlova, Rashida
Protsenko, Svetlana A.
Sarantseva, Ksenia A.
Stroyakovskiy, Daniil L.
Zinkovskaya, Anna V.
机构：
[1] N N Blokhin Russian Canc Res Ctr, Moscow, Russia
[2] Minist Hlth, Hertsen Moscow Oncol Res Inst, Natl Med Res Radiol Ctr, Moscow, Russia
[3] Natl Med Res Ctr Oncol n N Blokhin, Moscow, Russia
[4] N N Petrov Res Inst Oncol, St Petersburg, Russia
[5] Moscow Dept Hlth, Moscow City Oncol Hosp 62, Moscow, Russia
[6] Pavlov St Petersburg State Med Univ, R M Gorbacheva Mem Inst Children Hematol & Transp, St Petersburg, Russia
[7] St Petersburg Clin Res Ctr Specialized Types Med, St Petersburg, Russia
[8] City Clin Oncol Dispensary, St Petersburg, Russia
[9] Multinat Ctr Qual Life Res, St Petersburg, Russia
[10] St Petersburg State Univ, St Petersburg, Russia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21126
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21126
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Observational study of the efficacy of nivolumab (Nivo) as 2+line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim analysis.
    Laktionov, Konstantin K.
    Arzumanyan, Alla L.
    Bolotina, Larisa V.
    Breder, Valeriy Vladimirovich
    Buevich, Natalia N.
    Danilova, Anastasia
    Filippova, Elena A.
    Kornietskaya, Anna
    Kramchaninov, Mikhail M.
    Kushniruk, Eugenia K.
    Latipova, Dilorom Hamidovna
    Lipatova, Dana A.
    Moiseenko, Fedor Vladimirovich
    Nikitina, Tatiana P.
    Orlov, Sergey
    Orlova, Rashida
    Protsenko, Svetlana
    Sarantseva, Ksenia A.
    Stroyakovskiy, Dan Iii
    Ionova, Tatyana I.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Multicenter observational study of the efficacy and safety of nivolumab (Nivo) as 2+line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim analysis
    Laktionov, K.
    Arzumanyan, A.
    Bolotina, L.
    Breder, V.
    Buevich, N.
    Danilova, A.
    Filippova, E.
    Kornietskaya, A.
    Kramchaninov, M.
    Kushniruk, E.
    Latipova, D.
    Moiseenko, F.
    Nikitina, T.
    Orlov, S.
    Orlova, R.
    Protsenko, S.
    Sarantseva, K.
    Stroyakovskiy, D.
    Ionova, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Clinical outcomes and quality of life (QoL) in adults with advanced refractory non-small cell lung cancer (NSCLC) patients receiving nivolumab (Nivo) as 2+line treatment: Interim analysis of expanded access program
    Laktionov, K. K.
    Bolotina, L. V.
    Breder, V. V.
    Danilova, A. S.
    Moiseenko, F. V.
    Nikitina, T. P.
    Orlova, R. V.
    Filippova, E. A.
    Protsenko, S. A.
    Ionova, T. I.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Multicenter observational prospective study of nivolumab (Nivo) as 2+line treatment in advanced refractory NSCLC pts: Clinical and quality of life outcomes.
    Orlova, Rashida
    Laktionov, Konstantin
    Bolotina, Larisa
    Breder, Valeriy Vladimirovich
    Danilova, Anastasia
    Filippova, Elena
    Kornietskaya, Anna
    Kramchaninov, Mikhail
    Kushniruk, Eugenia
    Latipova, Dilorom
    Ledin, Evgeny
    Mochalova, Anastasia
    Moiseenko, Fedor Vladimirovich
    Nikitina, Tatiana
    Orlov, Sergey
    Protsenko, Svetlana
    Sarantseva, Ksenia
    Stroyakovskiy, Daniil
    Zinkovskaya, Anna
    Ionova, Tatyana
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Quality of Life and Clinical Outcomes of Nivolumab as 2+Line Treatment in Advanced Refractory NSCLC Pts: Interim Analysis
    Ionova, T.
    Arzumanyan, A.
    Bolotina, L.
    Breder, V.
    Buevich, N.
    Danilova, A.
    Filippova, E.
    Kornietskaya, A.
    Kramchaninov, M.
    Kushniruk, E.
    Latipova, D.
    Lipatova, D.
    Malova, O.
    Moiseenko, F.
    Nikitina, T.
    Orlov, S.
    Orlova, R.
    Protsenko, S.
    Sarantseva, K.
    Stroyakovsky, D.
    Zinkovskaya, A.
    Laktionov, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1915 - S1915
  • [6] Symptom analysis and quality of life (QoL) in patients treated with nivolumab (NIVO) as ≥2nd line therapy for advanced non-small cell lung cancer (aNSCLC)
    Schwartzberg, L.
    Chandler, J.
    Reynold, C.
    Garon, E. B.
    Stepanski, E. J.
    Keogh, G. P.
    Blankstein, K.
    Schneider, J.
    Korytowski, B.
    Sen, R.
    Coon, C.
    McDonald, J.
    Li, X.
    McCleod, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S628 - S629
  • [7] Patient attitude and survival in advanced non-small cell lung cancer (NSCLC): Results of a prospective observational study.
    Altug, S.
    Wang, L.
    Chu, D.
    Park, K.
    Hsu, H.
    Cok, G.
    Roubec, J.
    Patil, S.
    Damyanov, D.
    Reece, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 401S - 401S
  • [8] First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses
    Gettinger, S. N.
    Hellmann, M. D.
    Shepherd, F. A.
    Antonia, S. J.
    Brahmer, J.
    Chow, L. Q.
    Goldman, J.
    Juergens, R.
    Borghaei, H.
    Ready, N. E.
    Gerber, D. E.
    Nathan, F.
    Shen, Y.
    Harbison, C. T.
    Rizvi, N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S632 - S632
  • [9] Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)
    Hellmann, M. D.
    Rizvi, N.
    Gettinger, S. N.
    Goldman, J.
    Chow, L. Q.
    Juergens, R.
    Borghaei, H.
    Brahmer, J.
    Shen, Y.
    Harbison, C. T.
    Nathan, F.
    Ready, N. E.
    Antonia, S. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S632 - S633
  • [10] Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)
    Costantini, Adrien
    Corny, Jennifer
    Fallet, Vincent
    Renet, Sophie
    Friard, Sylvie
    Chouaid, Christos
    Duchemann, Boris
    Giroux-Leprieur, Etienne
    Taillade, Laurent
    Doucet, Ludovic
    Nguenang, Marina
    Jouveshomme, Stephane
    Wislez, Marie
    Tredaniel, Jean
    Cadranel, Jacques
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
12345